CML
4
Pipeline Programs
2
Companies
2
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
On Market (2)
Approved therapies currently available
U
NILOTINIBApproved
nilotinib
Unknown Companyoral2025
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Novartisnilotinib
Inhibikase TherapeuticsImatinib Mesylate
Clinical Trials (2)
Total enrollment: 93 patients across 2 trials
Tasigna in Glivec-resistant or Intolerant Patients in CML
Start: Feb 2009Est. completion: Sep 201293 patients
Phase 4Completed
A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg
Start: Dec 2022Est. completion: Dec 2024
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space